Vertex strikes two deals to double down on gene therapy 12-Jun-2019 By Ben Hargreaves Vertex agrees to acquire Exonics and to expand its collaboration with CRISPR Therapeutics, which sees it invest $420m in upfront payments to develop its position in gene therapy.